← Eichor
Study identifier: NCT06770621 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Longitudinal Study of the GLUcagon REsponse to Hypoglycemia in Children and Adolescents With New-onset Type 1 DIAbetes

Condition: Severe Hypoglycemia · Type1diabetes  ·  Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

PhaseNA
Planned participants1000
Who can joinAll sexes, 2 Years to 30 Years
Healthy volunteersYes

About this study

The GLUREDIA study investigates the counter-regulatory response (CRR) during hypoglycemia in children with type 1 diabetes (T1D). Hypoglycemia can lead to severe symptoms, but is normally counteracted by CRR, corresponding to the secretion of hormones to maintain normoglycemia. Hypoglycemia is common in T1DM but some patients develop severe hypoglycemia as a result of CRR dysfunction. Despite several studies in adults, the presence of CRR dysfunction remains unpredictable and not well understood. The objective of GLUREDIA is therefore to describe and predict the evolution of CRR in children with T1DM.

This description comes directly from the study's public registry record.

Talk to the study team

Philippe Lysy, Pr  ·  027641370  ·  antoine.harvengt@saintluc.uclouvain.be

Antoine Harvengt, Dr  ·  027641370  ·  antoine.harvengt@saintluc.uclouvain.be

Always discuss trial participation with your own doctor first.

Locations (1)

Clinique Universitaires Saint LucBrussels, Woluwe-saint-lambert, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06770621